Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone

Yaowaluck Hongkaew,1,2 Nattawat Ngamsamut,3 Apichaya Puangpetch,1,2 Natchaya Vanwong,1,2 Pornpen Srisawasdi,4 Montri Chamnanphon,1,2 Bhunnada Chamkrachchangpada,3 Teerarat Tan-kam,3 Penkhae Limsila,3 Chonlaphat Sukasem1,2 1Division of Pharmacogenomics and Personalized Medicine, Department...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, Chamkrachchangpada B, Tan-kam T, Limsila P, Sukasem C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a13191af583040abb2d95260cbc95ae1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a13191af583040abb2d95260cbc95ae1
record_format	dspace
spelling	oai:doaj.org-article:a13191af583040abb2d95260cbc95ae12021-12-02T00:48:48ZHyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone1178-2021https://doaj.org/article/a13191af583040abb2d95260cbc95ae12015-01-01T00:00:00Zhttp://www.dovepress.com/hyperprolactinemia-in-thai-children-and-adolescents-with-autism-spectr-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Yaowaluck Hongkaew,1,2 Nattawat Ngamsamut,3 Apichaya Puangpetch,1,2 Natchaya Vanwong,1,2 Pornpen Srisawasdi,4 Montri Chamnanphon,1,2 Bhunnada Chamkrachchangpada,3 Teerarat Tan-kam,3 Penkhae Limsila,3 Chonlaphat Sukasem1,2 1Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, 2Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Mahidol University, 3Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department of Mental Health Services, Ministry of Public Health, 4Division of Clinical Chemistry, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Abstract: Hyperprolactinemia is a common adverse effect observed in children with autism spectrum disorder (ASD) during pharmacotherapy with risperidone. The main aim of this study was to investigate important clinical factors influencing the prolactin response in risperidone-treated Thai ASD. A total of 147 children and adolescents (127 males and 20 females) aged 3–19 years with ASD received risperidone treatment (0.10–6.00 mg/day) for up to 158 weeks. Prolactin levels were measured by chemiluminescence immunoassay. The clinical data of patients collected from medical records – age, weight, height, body mass index, dose of risperidone, duration of treatment, and drug-use pattern – were recorded. Hyperprolactinemia was observed in 66 of 147 (44.90%) subjects. Median prolactin level at the high doses (24.00, interquartile range [IQR] 14.30–29.20) of risperidone was significantly found to be higher than at the recommended (16.20, IQR 10.65–22.30) and low (11.70, IQR 7.51–16.50) doses of risperidone. There was no relationship between prolactin levels and duration of risperidone treatment. Dose-dependence is identified as a main factor associated with hyperprolactinemia in Thai children and adolescents with ASD treated with risperidone. This study suggests that risperidone treatment causes prolactin elevations and the effects of risperidone on prolactin are probably dose-related in pediatric patients. Keywords: prolactin level, risperidone, autism spectrum disorders, Thai, hyperprolactinemiaHongkaew YNgamsamut NPuangpetch AVanwong NSrisawasdi PChamnanphon MChamkrachchangpada BTan-kam TLimsila PSukasem CDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 191-196 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Hongkaew Y Ngamsamut N Puangpetch A Vanwong N Srisawasdi P Chamnanphon M Chamkrachchangpada B Tan-kam T Limsila P Sukasem C Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
description	Yaowaluck Hongkaew,1,2 Nattawat Ngamsamut,3 Apichaya Puangpetch,1,2 Natchaya Vanwong,1,2 Pornpen Srisawasdi,4 Montri Chamnanphon,1,2 Bhunnada Chamkrachchangpada,3 Teerarat Tan-kam,3 Penkhae Limsila,3 Chonlaphat Sukasem1,2 1Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, 2Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Mahidol University, 3Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department of Mental Health Services, Ministry of Public Health, 4Division of Clinical Chemistry, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Abstract: Hyperprolactinemia is a common adverse effect observed in children with autism spectrum disorder (ASD) during pharmacotherapy with risperidone. The main aim of this study was to investigate important clinical factors influencing the prolactin response in risperidone-treated Thai ASD. A total of 147 children and adolescents (127 males and 20 females) aged 3–19 years with ASD received risperidone treatment (0.10–6.00 mg/day) for up to 158 weeks. Prolactin levels were measured by chemiluminescence immunoassay. The clinical data of patients collected from medical records – age, weight, height, body mass index, dose of risperidone, duration of treatment, and drug-use pattern – were recorded. Hyperprolactinemia was observed in 66 of 147 (44.90%) subjects. Median prolactin level at the high doses (24.00, interquartile range [IQR] 14.30–29.20) of risperidone was significantly found to be higher than at the recommended (16.20, IQR 10.65–22.30) and low (11.70, IQR 7.51–16.50) doses of risperidone. There was no relationship between prolactin levels and duration of risperidone treatment. Dose-dependence is identified as a main factor associated with hyperprolactinemia in Thai children and adolescents with ASD treated with risperidone. This study suggests that risperidone treatment causes prolactin elevations and the effects of risperidone on prolactin are probably dose-related in pediatric patients. Keywords: prolactin level, risperidone, autism spectrum disorders, Thai, hyperprolactinemia
format	article
author	Hongkaew Y Ngamsamut N Puangpetch A Vanwong N Srisawasdi P Chamnanphon M Chamkrachchangpada B Tan-kam T Limsila P Sukasem C
author_facet	Hongkaew Y Ngamsamut N Puangpetch A Vanwong N Srisawasdi P Chamnanphon M Chamkrachchangpada B Tan-kam T Limsila P Sukasem C
author_sort	Hongkaew Y
title	Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
title_short	Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
title_full	Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
title_fullStr	Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
title_full_unstemmed	Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
title_sort	hyperprolactinemia in thai children and adolescents with autism spectrum disorder treated with risperidone
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/a13191af583040abb2d95260cbc95ae1
work_keys_str_mv	AT hongkaewy hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT ngamsamutn hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT puangpetcha hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT vanwongn hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT srisawasdip hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT chamnanphonm hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT chamkrachchangpadab hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT tankamt hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT limsilap hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone AT sukasemc hyperprolactinemiainthaichildrenandadolescentswithautismspectrumdisordertreatedwithrisperidone
_version_	1718403456913375232

Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone

Ejemplares similares